Arbutus Biopharma (ABUS) Common Equity (2016 - 2025)
Historic Common Equity for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $77.4 million.
- Arbutus Biopharma's Common Equity fell 2759.0% to $77.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.4 million, marking a year-over-year decrease of 2759.0%. This contributed to the annual value of $97.4 million for FY2024, which is 816.09% down from last year.
- According to the latest figures from Q3 2025, Arbutus Biopharma's Common Equity is $77.4 million, which was down 2759.0% from $83.0 million recorded in Q2 2025.
- Arbutus Biopharma's 5-year Common Equity high stood at $169.4 million for Q4 2021, and its period low was $77.4 million during Q3 2025.
- Over the past 5 years, Arbutus Biopharma's median Common Equity value was $119.3 million (recorded in 2023), while the average stood at $121.1 million.
- As far as peak fluctuations go, Arbutus Biopharma's Common Equity surged by 6617.21% in 2021, and later plummeted by 3223.9% in 2025.
- Arbutus Biopharma's Common Equity (Quarter) stood at $169.4 million in 2021, then dropped by 19.23% to $136.9 million in 2022, then dropped by 22.53% to $106.0 million in 2023, then dropped by 8.16% to $97.4 million in 2024, then dropped by 20.51% to $77.4 million in 2025.
- Its Common Equity was $77.4 million in Q3 2025, compared to $83.0 million in Q2 2025 and $79.2 million in Q1 2025.